Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1149 | 946 | 1232 | 1212 | 1766 | 2401 |
Fund Return | 14.9% | -5.39% | 23.24% | 6.63% | 12.05% | 9.15% |
Place in category | 22 | 104 | 39 | 25 | 4 | 30 |
% in Category | 10 | 65 | 24 | 12 | 3 | 28 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Prudential Jennison Growth Z | 4.44B | 30.35 | 6.57 | 15.96 | ||
Prudential Jennison Global Opps Z | 3.29B | 24.89 | 0.78 | 14.36 | ||
Prudential Jennison Utility A | 2.73B | 37.53 | 12.23 | 8.83 | ||
Prudential Jennison Small Company Q | 2.13B | 21.79 | 5.20 | 10.54 | ||
Prudential Jennison Growth A | 2.08B | 30.03 | 6.25 | 15.61 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Health Care Adm | 37.96B | 5.49 | 5.82 | 7.98 | ||
Fidelity Select Health Care | 6.77B | 13.38 | 2.97 | 9.10 | ||
T. Rowe Price Health Sciences | 7.83B | 10.22 | 0.91 | 9.64 | ||
Vanguard Health Care Inv | 6.88B | 5.45 | 5.77 | 7.93 | ||
Fidelity Advisor Health Care A | 1.33B | 11.89 | 2.31 | 8.23 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 12.44 | 765.10 | -2.16% | |
UnitedHealth | US91324P1021 | 5.62 | 513.67 | +0.13% | |
Bristol-Myers Squibb | US1101221083 | 4.56 | 56.68 | +0.19% | |
argenx ADR | US04016X1019 | 4.49 | 645.37 | +3.88% | |
Boston Scientific | US1011371077 | 4.18 | 91.29 | +0.66% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review